NCT01849874 2023-10-30A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal CancerPfizerPhase 3 Terminated341 enrolled 15 charts
NCT01763164 2021-03-22Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive MelanomaPfizerPhase 3 Completed402 enrolled 21 charts